Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 262

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 262
---
d) | Disclosed in the report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |

| (5) | I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |

| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |

| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |

| Dated: March 28, 2025 | By: | /s/ Manuel Litchman                                                         |
|:----------------------|:----|:----------------------------------------------------------------------------|
|                       |     | Manuel Litchman, M.D.                                                       |
|                       |     | President, Chief Executive Officer and Interim Chief Financial Officer      |
|                       |     | -Principal Executive Officer and Principal Financial and Accounting Officer |

​

<div align='center'>​</div>

EXHIBIT 32.1

<div align='center'>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>

In connection with the Annual Report on Form 10-K
of Mustang Bio, Inc. (the “Company”) for the period ended December 31, 2024, as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), I, Manuel Litchman, M.D., President, Chief Executive Officer and Interim Chief
Financial Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 193